Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
Friday, February 6th, 2009CHARLOTTESVILLE, VA – February 6, 2009 – Diffusion Pharmaceuticals LLC, a clinical-stage drug development company commercializing first-in-class drugs that enhance oxygen diffusion, today announced the completion of a $2.9 million private placement. The proceeds will support the company’s overall growth and clinical programs for its lead drug compound, trans sodium crocetinate (TSC). In addition, David [...]
